Another PPAR-γ agonist, rosiglitazone, attenuated the progression of renal disease by inhibiting TGF-β expression in Han:SPRD-Cy rats and inhibited TGF-β-mediated fibrogenes in ADPKD cyst-lining epithelial cells [34], [35]. The gene discussed is TGFB1; the disease is autosomal dominant polycystic kidney disease.